HDAC9 and Thrombocytopenia: The HDAC inhibitors are generally well tolerated as monotherapy with the most common reported adverse events of grade 3 or more being thrombocytopenia, neutropenia, gastrointestinal symptoms and fatigue [8, 12, 13].